Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print April 25, 2007, doi:10.1212/01.wnl.0000260269.93245.d2)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
01.wnl.0000260269.93245.d2v1
68/21/1800    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Received September 18, 2006
Accepted January 21, 2007

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial

ADAPT Research Group

From Johns Hopkins Bayview and Johns Hopkins School of Medicine(G.G.L.), Baltimore; VA Puget Sound Health Care System and University of Washington (J.C.S.B.), Seattle; Boston University School of Medicine (R.C.G.), MA; Johns Hopkins Bloomberg School of Public Health (C.M.), Baltimore; Johns Hopkins School of Medicine (S.P.), Baltimore, MD; and Sun Health Research Institute (M.S.), Sun City, AZ.


Abstract Objective: To evaluate the efficacy and safety of naproxen and celecoxib for the primary prevention of Alzheimer disease (AD). Methods: Randomized, placebo-controlled, double-masked clinical trial conducted at six US dementia research clinics. Volunteers aged 70+ years, with cognitive screening scores above designated cut-offs and a family history of AD, were randomly assigned to celecoxib 200 mg BID, naproxen sodium 220 mg BID, or placebo. Enrollment began in early 2001. The main outcome measure was diagnosis of AD after randomization. Results: On December 17, 2004, treatments were suspended. Events while on treatment yielded hazard ratios vs placebo of 1.99 (95% CI 0.80 to 4.97; p = 0.14) for celecoxib and 2.35 (0.95 to 5.77; p = 0.06) for naproxen. Imperfect screening measures led to enrollment of 7 individuals with dementia and 46 others with milder cognitive syndromes. Their (prevalent) illness was detected at enrollment and diagnosed within 6 months following randomization. Secondary analyses that excluded the 7 cases of prevalent dementia showed increased hazard ratios for AD with both treatments. Neither treatment produced a notable effect on the incidence of milder cognitive syndromes. Conclusions:These results do not support the hypothesis that celecoxib or naproxen prevent Alzheimer dementia, at least within the early years after initiation of treatment. Masked long-term follow-up of these participants will be essential.




This article has been cited by other articles:


Home page
 NeurologyHome page
J.C.S. Breitner, S. J.P.A. Haneuse, R. Walker, S. Dublin, P. K. Crane, S. L. Gray, and E. B. Larson
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort
Neurology, June 2, 2009; 72(22): 1899 - 1905.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. A. Bennett and R. A. Whitmer
NSAID exposure and risk of Alzheimer disease: Is timing everything?
Neurology, June 2, 2009; 72(22): 1884 - 1885.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
B. K. Martin, J. Brandt, J. C. S. Breitner, S. Craft, D. Evans, R. Green, M. Mullan, S. Piantadosi, and C. Szekely
Can Treatment With Nonsteroidal Anti-inflammatory Drugs Protect From Dementia?--Reply
Arch Neurol, April 1, 2009; 66(4): 540 - 540.
[Full Text] [PDF]

Home page
 Epidemiol RevHome page
N. Coley, S. Andrieu, V. Gardette, S. Gillette-Guyonnet, C. Sanz, B. Vellas, and A. Grand
Dementia Prevention: Methodological Explanations for Inconsistent Results
Epidemiol. Rev., November 1, 2008; 30(1): 35 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
M. Sano, D. Jacobs, H. Andrews, K. Bell, N. Graff-Radford, J. Lucas, P. Rabins, K. Bolla, W.-Y. Tsai, P. Cross, et al.
A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics
Clinical Trials, October 1, 2008; 5(5): 523 - 533.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
ADAPT Research Group
Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib
Arch Neurol, July 1, 2008; 65(7): 896 - 905.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. A. Szekely, R. C. Green, J.C.S. Breitner, T. Ostbye, A. S. Beiser, M. M. Corrada, H. H. Dodge, M. Ganguli, C. H. Kawas, L. H. Kuller, et al.
No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
Neurology, June 10, 2008; 70(24): 2291 - 2298.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
Z. Arvanitakis, F. Grodstein, J. L. Bienias, J. A. Schneider, R. S. Wilson, J. F. Kelly, D. A. Evans, and D. A. Bennett
Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Neurology, June 3, 2008; 70(23): 2219 - 2225.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. C. Vlad, D. R. Miller, N. W. Kowall, and D. T. Felson
Protective effects of NSAIDs on the development of Alzheimer disease
Neurology, May 6, 2008; 70(19): 1672 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al.
Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity
Brain, March 1, 2008; 131(3): 651 - 664.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
C. Patterson MD, J. W. Feightner MD MSc, A. Garcia MD PhD, G.-Y. R. Hsiung MD MHSc, C. MacKnight MD MSc, and A. D. Sadovnick PhD
Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
Can. Med. Assoc. J., February 26, 2008; 178(5): 548 - 556.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
P. B. Gorelick and J. V. Bowler
Advances in Vascular Cognitive Impairment 2007
Stroke, February 1, 2008; 39(2): 279 - 282.
[Full Text] [PDF]

Home page
 NeurologyHome page
J. Rogers and M. N. Sabbagh
Interactions of stroke, nonsteroidal anti-inflammatory drugs, and APOE status in dementia risk
Neurology, January 1, 2008; 70(1): 5 - 6.
[Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. P. Imbimbo, E. Del Giudice, D. Colavito, A. D'Arrigo, M. D. Carbonare, G. Villetti, F. Facchinetti, R. Volta, V. Pietrini, M. F. Baroc, et al.
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel {gamma}-Secretase Modulator, Reduces Brain beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 822 - 830.
[Abstract] [Full Text] [PDF]

Home page
 JWatch NeurologyHome page
Inflammation Subsiding as a Suspect in Cognitive Disorders of Aging
Journal Watch Neurology, August 14, 2007; 2007(814): 1 - 1.
[Full Text]

Home page
 NeurologyHome page
J. M. Scharf and K. R. Daffner
NSAIDs in the prevention of dementia: A Cache-22?
Neurology, July 17, 2007; 69(3): 235 - 236.
[Full Text] [PDF]

Home page
 JWatch GeneralHome page
Can NSAIDs Prevent Alzheimer Disease?
Journal Watch (General), May 29, 2007; 2007(529): 1 - 1.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by AAN Enterprises, Inc.